Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

GREY:IMVIF - Post Discussion

IMV Inc > Presenting on Friday 10th at 2 pm
View:
Post by antisense on Feb 08, 2023 11:18am

Presenting on Friday 10th at 2 pm

IMV is presenting their data on Friday Feb 10 at 2 pm at the conference:

  • 2:00 pm

  • Delivery Matters: Leveraging the DPX Cancer Vaccine Platform to Educate Sustained Anti-cancer Immunity and Durable Clinical Benefit

    This talk addresses:

    • The unique capability of the DPX vaccine platform to package diverse immune cargo (Neo- and tumor-associated antigens, immune modulators) into a single formulation for delivery to APCs and flow through lymph nodes.
    • The phase 2 clinical experience with the lead DPX asset, Maveropepimut-S (MVP-S), shows clear evidence of sustained immune response and deep, durable clinical benefit.
    • Updates on patient responses including complete responses in relapsed/ refractory DLBCL, advanced ovarian cancers and metastatic bladder cancers.


    Jeremy Graff, PhD
    CSO, IMV Inc

    https://theconferenceforum.org/conferences/immuno-oncology-360/2023-agenda/#day-93648-tab

Be the first to comment on this post
IMV Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities